Bmab-1000(Bmab-1000) - 在研适应症：骨质疏松症_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

BMAB 1000、BMAB1000

靶点-

作用机制-

治疗领域

内分泌与代谢疾病皮肤和肌肉骨骼疾病

在研适应症

骨质疏松症

非在研适应症-

原研机构

Biocon Biologics Ltd. (India)

在研机构

Biocon Biologics Ltd. (India)

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Bmab-1000 相关的临床试验

NCT05345691 / Completed临床3期

A Randomized, Double-Blind, Multicenter, Parallel-Arm Phase 3 Study to Compare the Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis

This is a randomized, double-blind, multicenter, parallel-arm, Phase 3 study to compare the efficacy, PK (Pharmacokinetic), PD (Pharmacodynamic), safety, and immunogenicity of Bmab 1000 and Prolia® in postmenopausal women with osteoporosis

开始日期2022-05-24

申办/合作机构

Biocon Ltd.

NCT05323708 / Completed临床1期

A Randomized, Double-blind, Two-arm, Single-dose, Parallel-Group Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy Volunteers

This study is to compare the Pharmacokinetics, Pharmacodynamics, safety, and tolerability of Bmab 1000 and Prolia® in normal healthy volunteers.

开始日期2022-03-09

申办/合作机构

Biotrial Research SAS

100 项与 Bmab-1000 相关的临床结果

登录后查看更多信息

100 项与 Bmab-1000 相关的转化医学

登录后查看更多信息

100 项与 Bmab-1000 相关的专利（医药）

登录后查看更多信息

100 项与 Bmab-1000 相关的药物交易

登录后查看更多信息